DUR 928

Drug Profile

DUR 928

Alternative Names: DUR-928; DV-928

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Virginia Commonwealth University
  • Developer DURECT Corporation
  • Class Anti-inflammatories; Antipsoriatics; Small molecules
  • Mechanism of Action Inflammation mediator modulators; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholic hepatitis; Primary sclerosing cholangitis
  • Phase I Acute kidney injury; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Psoriasis
  • Preclinical Liver disorders; Stroke

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Non-alcoholic-fatty-liver-disease(In volunteers) in Australia (PO, Powder)
  • 01 Mar 2018 DURECT plans a proof-of-concept phase II trial for Psoriasis trial in the third quarter of 2018 (Topical)
  • 14 Feb 2018 Durect plans a phase II trial for Alcoholic-hepatitis in USA in February 2018 (IV) , (NCT03432260)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top